Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis

Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho

Clin Mol Hepatol. 2024;30(3):561-576. Published online June 3, 2024

DOI: https://doi.org/10.3350/cmh.2023.0384

View: 2311 Download: 120 Web of Science: 1 Crossref: 1

Review

Risk factors in nonalcoholic fatty liver disease

Eunji Ko, Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2023;29(Suppl):S79-S85. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0398

View: 5050 Download: 242 Web of Science: 25 Crossref: 26

Original Article

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity

Hong-Kyu Kim, Sung-Jin Bae, Min Jung Lee, Eun Hee Kim, Hana Park, Hwi Seung Kim, Yun Kyung Cho, Chang Hee Jung, Woo Je Lee, Jaewon Choe

Clin Mol Hepatol. 2023;29(4):987-1001. Published online July 5, 2023

DOI: https://doi.org/10.3350/cmh.2023.0035

View: 4624 Download: 295 Web of Science: 13 Crossref: 15

Editorial

Lean or Non-obese Nonalcoholic Fatty Liver Disease Patients: Are They Really Lean?

Eugene Han, Yong-ho Lee

Clin Mol Hepatol. 2023;29(4):980-983. Published online August 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0250

View: 2265 Download: 102 Web of Science: 2 Crossref: 2

Implications of comorbidities in nonalcoholic fatty liver disease

Sherlot Juan Song, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0066

View: 3554 Download: 87 Web of Science: 3 Crossref: 2

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?

Heejoon Jang, Won Kim

Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0088

View: 3218 Download: 91 Web of Science: 2 Crossref: 3

Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?

Ho Soo Chun, Minjong Lee

Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023

DOI: https://doi.org/10.3350/cmh.2023.0061

View: 2935 Download: 102 Web of Science: 2 Crossref: 1

Review

Impact of diabetes, obesity, and dyslipidemia on the risk of hepatocellular carcinoma in patients with chronic liver diseases

Hwang Sik Shin, Baek Gyu Jun, Sang-Wook Yi

Clin Mol Hepatol. 2022;28(4):773-789. Published online August 8, 2022

DOI: https://doi.org/10.3350/cmh.2021.0383

View: 5571 Download: 260 Web of Science: 27 Crossref: 29

Original Article

Systematic review with meta-analysis: Non-alcoholic fatty liver disease and the association with pregnancy outcomes

Hydar El Jamaly, Guy D Eslick, Martin Weltman

Clin Mol Hepatol. 2022;28(1):52-66. Published online September 17, 2021

DOI: https://doi.org/10.3350/cmh.2021.0205

View: 7405 Download: 231 Web of Science: 14 Crossref: 17

Obesity and the risk of primary liver cancer: A systematic review and meta-analysis

Won Sohn, Hyun Woong Lee, Sangheun Lee, Jin Hong Lim, Min Woo Lee, Chan Hyuk Park, Seung Kew Yoon

Clin Mol Hepatol. 2021;27(1):157-174. Published online November 26, 2020

DOI: https://doi.org/10.3350/cmh.2020.0176

View: 10489 Download: 419 Web of Science: 86 Crossref: 90

Editorial

Metabolic disease as a risk of hepatocellular carcinoma

Naoshi Nishida

Clin Mol Hepatol. 2021;27(1):87-90. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0302

View: 5196 Download: 114 Web of Science: 12 Crossref: 14

Letter to the Editor

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?

Dimitrios Patoulias, Michael Doumas

Clin Mol Hepatol. 2020;26(4):582-583. Published online September 25, 2020

DOI: https://doi.org/10.3350/cmh.2020.0264

View: 3846 Download: 69 Web of Science: 2 Crossref: 2

Review

Application of transient elastography in nonalcoholic fatty liver disease

Xinrong Zhang, Grace Lai-Hung Wong, Vincent Wai-Sun Wong

Clin Mol Hepatol. 2020;26(2):128-141. Published online November 8, 2019

DOI: https://doi.org/10.3350/cmh.2019.0001n

View: 15244 Download: 570 Web of Science: 67 Crossref: 72

Original Article

Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard

Jamak Modaresi Esfeh, Kaveh Hajifathalian, Kianoush Ansari-Gilani

Clin Mol Hepatol. 2020;26(1):54-59. Published online November 15, 2019

DOI: https://doi.org/10.3350/cmh.2019.0039

View: 8880 Download: 204 Web of Science: 48 Crossref: 50

Protein and vitamin B6 intake are associated with liver steatosis assessed by transient elastography, especially in obese individuals

Yvelise Ferro, Ilaria Carè, Elisa Mazza, Francesco Provenzano, Carmela Colica, Carlo Torti, Stefano Romeo, Arturo Pujia, Tiziana Montalcini

Clin Mol Hepatol. 2017;23(3):249-259. Published online July 28, 2017

DOI: https://doi.org/10.3350/cmh.2017.0019

View: 13227 Download: 157 Web of Science: 19 Crossref: 22

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B

Jaemin Lee, Sun Hong Yoo, Won Sohn, Hyung Woo Kim, Yong Sun Choi, Jung Ho Won, Jin Young Heo, Sang Jong Park, Young Min Park

Clin Mol Hepatol. 2016;22(3):339-349. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0021

View: 12094 Download: 165 Web of Science: 19 Crossref: 20

Editorial

Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients?

Byoung Kuk Jang

Clin Mol Hepatol. 2016;22(3):336-338. Published online September 25, 2016

DOI: https://doi.org/10.3350/cmh.2016.0104

View: 8352 Download: 118 Web of Science: 2 Crossref: 1

Original Article

Clinical impacts of hazardous alcohol use and obesity on the outcome of entecavir therapy in treatment-naïve patients with chronic hepatitis B infection

Won Gil Chung, Hong Joo Kim, Young Gil Choe, Hyo Sun Seok, Chang Wook Chon, Yong Kyun Cho, Byung Ik Kim, Young Yool Koh

Clin Mol Hepatol. 2012;18(2):195-202. Published online June 26, 2012

DOI: https://doi.org/10.3350/cmh.2012.18.2.195

View: 9539 Download: 73 Crossref: 12

3

Clinical Characteristics of Factory Workers with Asymptomatic Liver Function Test Abnormalities found on Serial Health Examination

Kang Mo Kim, M.D., Yoon Jun Kim, M.D., Kwang Hyuck Lee, M.D. and Domyung Paek, M.D., M.Sc., S.D.

Clin Mol Hepatol. 2005;11(2):144-156. Published online January 1, 2000

View: 2522 Download: 24

1 |

Viewed By 5163	MAFLD: How is it different from NAFLD?
Viewed By 4909	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4875	Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Viewed By 4604	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 4576	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 219	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 155	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 134	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 119	MAFLD: How is it different from NAFLD?
Cited By 96	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search